ALNYLAM PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Financing Activities in USD from Q1 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Alnylam Pharmaceuticals, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2010 to Q1 2025.
  • Alnylam Pharmaceuticals, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $44.1M, a 52.5% increase year-over-year.
  • Alnylam Pharmaceuticals, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $294M, a 70.9% increase from 2023.
  • Alnylam Pharmaceuticals, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $172M, a 59.6% decline from 2022.
  • Alnylam Pharmaceuticals, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $426M, a 65.9% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

ALNYLAM PHARMACEUTICALS, INC. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $44.1M +$15.2M +52.5% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-01
Q1 2024 $28.9M -$17.5M -37.7% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-01
Q1 2023 $46.4M +$11.4M +32.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q1 2022 $35M -$16.2M -31.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q1 2021 $51.2M -$2.69M -5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-28
Q1 2020 $53.9M -$337M -86.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q1 2019 $391M +$349M +842% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q1 2018 $41.5M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q1 2013 $178M +$90.9M +104% Jan 1, 2013 Mar 31, 2013 10-Q 2013-05-07
Q1 2012 $87.3M +$87.3M Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-07
Q1 2011 $9K* -$533K Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-03
Q1 2010 $542K Jan 1, 2010 Mar 31, 2010 10-Q 2011-05-05

ALNYLAM PHARMACEUTICALS, INC. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $294M +$122M +70.9% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-13
2023 $172M -$254M -59.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-13
2022 $426M -$821M -65.9% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-13
2021 $1.25B +$252M +25.3% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-15
2020 $995M +$172M +20.9% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 $823M +$758M +1157% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-10
2018 $65.5M -$1.06B -94.2% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-11
2017 $1.12B +$947M +533% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-13
2016 $178M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-14
2013 $201M +$108M +115% Jan 1, 2013 Dec 31, 2013 10-K 2014-02-20
2012 $93.4M +$92.7M +12557% Jan 1, 2012 Dec 31, 2012 10-K 2014-02-20
2011 $738K -$2.93M -79.9% Jan 1, 2011 Dec 31, 2011 10-K 2014-02-20
2010 $3.66M Jan 1, 2010 Dec 31, 2010 10-K 2013-02-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.